|
Video: What is a Stock Split?
|
|
NewLink Genetics is a clinical-stage immuno-oncology company focused on discovering and developing immunotherapeutic products for the treatment of patients with cancer. Co.'s small-molecule product candidates in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway. Co.'s product candidates include: indoximod and NLG802 (a prodrug of indoximod), which are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer; and NLG207, which is a nanoparticle-drug conjugate consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor of the topoisomerase-1 inhibitor, camptothecin. According to our NLNK stock split history records, NLNK has had 0 splits. | |
|
NLNK (NLNK) has 0 splits in our NLNK stock split history database.
Looking at the NLNK stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NLNK shares, starting with a $10,000 purchase of NLNK, presented on a split-history-adjusted basis factoring in the complete NLNK stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
03/18/2020 |
|
Start price/share: |
$21.58 |
|
End price/share: |
$0.89 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.88% |
|
Average Annual Total Return: |
-41.80% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$412.38 |
|
Years: |
5.89 |
|
|
|
|
|